Search

Your search keyword '"Opelz, G."' showing total 1,766 results
Start Over Author "Opelz, G."
1,766 results on '"Opelz, G."'

5. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

Author

Süsal, Caner (ORCID 0000-0003-2521-8201 & YÖK ID 351800), Morath, C.; Schmitt, A.; Schmitt, M.; Wang, L.; Kleist, C.; Opelz, G.; Tran, T.H.; Scherer, S.; Schwenger, V.; Kemmner, S.; Fischereder, M.; Stangl, M.; Hauser, I.A.; Sommerer, C.; Nusshag, C.; Kalble, F.; Speer, C.; Benning, L.; Bischofs, C.; Sauer, S.; Schubert, M.L.; Kunz, A.; Hückelhoven-Krauss, A.; Neuber, B.; Mehrabi, A.; Schwab, C.; Waldherr, R.; Sander, A.; Büsch, C.; Czock, D.; Böhmig, G.A.; Reiser, J.; Roers, A.; Müller-Tidow, C.; Terness, P.; Zeier, M.; Daniel, V.; Schaier, M., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Süsal, Caner (ORCID 0000-0003-2521-8201 & YÖK ID 351800), Morath, C.; Schmitt, A.; Schmitt, M.; Wang, L.; Kleist, C.; Opelz, G.; Tran, T.H.; Scherer, S.; Schwenger, V.; Kemmner, S.; Fischereder, M.; Stangl, M.; Hauser, I.A.; Sommerer, C.; Nusshag, C.; Kalble, F.; Speer, C.; Benning, L.; Bischofs, C.; Sauer, S.; Schubert, M.L.; Kunz, A.; Hückelhoven-Krauss, A.; Neuber, B.; Mehrabi, A.; Schwab, C.; Waldherr, R.; Sander, A.; Büsch, C.; Czock, D.; Böhmig, G.A.; Reiser, J.; Roers, A.; Müller-Tidow, C.; Terness, P.; Zeier, M.; Daniel, V.; Schaier, M., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine

Abstract

Introduction: donor-derived modified immune cells (MIC) induced long-term specific immunosuppression against the allogeneic donor in preclinical models of transplantation. In a phase I clinical trial (TOL-1 Study), MIC treatment resulted in a cellular phenotype that was directly and indirectly suppressive to the recipient's immune system allowing for reduction of conventional immunosuppressive therapy. Here, we describe a protocol for a randomised controlled, multicentre phase-IIb clinical trial of individualised immunosuppression with intravenously administered donor MIC compared with standard-of-care (SoC) in living donor kidney transplantation (TOL-2 Study). Methods and analysis: sixty-three living donor kidney transplant recipients from six German transplant centres are randomised 2:1 to treatment with MIC (MIC group, N=42) or no treatment with MIC (control arm, N=21). MIC are manufactured from donor peripheral blood mononuclear cells under Good Manufacturing Practice conditions. The primary objective of this trial is to determine the efficacy of MIC treatment together with reduced conventional immunosuppressive therapy in terms of achieving an operational tolerance-like phenotype compared with SoC 12 months after MIC administration. Key secondary endpoints are the number of patient-relevant infections as well as a composite of biopsy-proven acute rejection, graft loss, graft dysfunction or death. Immunosuppressive therapy of MIC-treated patients is reduced during follow-up under an extended immunological monitoring including human leucocyte antigen-antibody testing, and determination of lymphocyte subsets, for example, regulatory B lymphocytes (Breg) and antidonor T cell response. A Data Safety Monitoring Board has been established to allow an independent assessment of safety and efficacy. Ethics and dissemination: ethical approval has been provided by the Ethics Committee of the Medical Faculty of the University of Heidelberg, Heidelberg, Germany (AFmu-580/202, Preparation of the study was funded by the Federal Ministry of Education and Research, Berlin, Germany (FKZ 161B0560A, 161B0560B, and FKZ 031B0560A, 031B0560B), and TolerogenixX GmbH, Heidelberg, Germany (N/A). Conduct of the study is funded by TolerogenixX GmbH (N/A).

Published
2022

17. Evaluation of the permissible mismatch concept

Author

Wujciak, T., Opelz, G., Mühlbacher, Ferdinand, editor, Gnant, M., editor, Klepetko, W., editor, Längle, F., editor, Laufer, G., editor, Sautner, T., editor, Steininger, R., editor, Wamser, P., editor, and Kootstra, G., editor

Published
1996
Full Text
View/download PDF

34. Minor H antigen matches and mismatches are equally distributed among recipients with or without complications after HLA identical sibling renal transplantation

Author

Dierselhuis, M. P., Spierings, E., Drabbels, J., Hendriks, M., Alaez, C., Alberú, J., Alvarez, M. B., Burlingham, W., Campos, E., Christiaans, M., Claas, F., Fasano, M. E., Gerbase-DeLima, M., Gervais, T., Gorodezky, C., Larriba, J., Lardy, N. M., Latinne, D., Morales-Buenrostro, L.-E., Moreno, M. J., Oguz, F., Opelz, G., Sergeant, R., Tambutti, M., Teper, S., Tilanus, M., Turkmen, A., Warrens, A. N., Weimar, W., and Goulmy, E.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results